ACR
Acrux Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
-16.65%
Annual Growth
5 years average annual growth
💰
9.09%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
2
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
📈 Performance
Price History
-98.05%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
9.09%
💰 Annual Dividend Earnings Per $1,000 invested**
$90.91
💰 Most Recent Dividend Franked Percentage Estimate
100.00%
💰 Average Dividend Franked Percentage Estimate
100.00 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of ACR, your last dividend payment(s) would have been:
$ 1,207.24
on Thu Sep 03 2015
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2025
$0.00
0.00%
2024
$0.00
0.00%
2023
$0.00
0.00%
2022
$0.00
0.00%
2021
$0.00
0.00%
2020
$0.00
0.00%
2019
$0.00
0.00%
2018
$0.00
0.00%
2017
$0.00
0.00%
2016
$0.00
0.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🍃 Environmental, Social and Governance scores ℹ️
🌳
Environmental Score
7
A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution
⚖️
Governance Score
58
An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.
🤓 Advanced information
Technical Info
💰 Price*
$0.03
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ACR
2
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
14 weeks
💵 Average investment amount
$17,891
⏰ Last time a customer invested in ACR
26 days
ACR investor breakdown
💵 Income of investors
More than 200k
33%
150k - 200k
33%
100k - 150k
50k - 100k
33%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in ACR also invest in...
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
🙌 Performance (5Yr p.a)
74.29%
📊 Share price
$13.20 AUD
📦 LOGISTICS
IAF.AX was created on 2012-03-12 by iShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The fund aims to provide investors with the performance of the Bloomberg AusBond Composite 0+ Yr IndexSM, before fees and expenses. The index is designed to measure the performance of the Australian bond market and includes investment grade fixed income securities issued by the Australian Treasury,
🙌 Performance (5Yr p.a)
-2.41%
📊 Share price
$100.77 AUD
VAF.AX was created on 2012-10-29 by Vanguard. The fund's investment portfolio concentrates primarily on investment grade fixed income. Vanguard Australian Fixed Interest Index ETF seeks to track the return of the Bloomberg AusBond Composite 0+ Yr Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
-2.63%
📊 Share price
$45.23 AUD
IVV
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
19.54%
📊 Share price
$63.85 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
AAA.AX was created on 2012-03-06 by BetaShares. The fund's investment portfolio concentrates primarily on target outcome asset allocation. The Fund aims to provide exposure to Australian cash, with attractive and regular incomedistributions that exceed the 30 day Bank Bill Swap Rate (after fees and expenses).
🙌 Performance (5Yr p.a)
0.04%
📊 Share price
$50.21 AUD
📞 COMMUNICATIONS
Want more shares? Try these...
Accent Resources NL engages in the exploration of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-08-26. Its exploration is focused on the discovery and development of iron ore, base metal and precious metal deposits in its project areas in Western Australia. Its projects include Magnetite Range and Norseman. The Magnetite Range project is an advanced iron project, with greenfield gold potential, located approximately 260 kilometers (km) east southeast of Geraldton and immediately adjacent, and along strike of the operating Extension Hill iron ore mine. The Extension Hill project is also referred to as the Mt Gibson project. Magnetite Range project occurs west of the Great Northern Highway between Wubin and Paynes Find and consists of granted mining lease M59/166, granted exploration licenses E59/875 and 1732 and granted PL59/1952. The Norseman project, comprising five mining leases and eight prospecting licenses covering an area of approximately 338 hectares, is located five km south of Norseman in the Dundas Mineral Field.
🙌 Performance (5Yr p.a)
4.00%
📊 Share price
$0.01 AUD
⛏️ MINING
Acumentis Group Ltd. engages in the provision of valuation, research, and advisory services in relation to property and businesses. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-05. The firm provides commercial and residential valuations, research, and property advice to various homeowners, investors, developers, and lenders. The company offers property valuation, insurance valuation, and advisory services to clients, including banks and financial institutions, property developers, property trusts, government, lawyers, accountants, real estate agents and independent retailers. Its services include quantity surveying, acquisition and compensation, capital gains tax, family law and legal, fund forecasts, illicit substance screening, insurance valuation, litigation and legal advisory services, property buyers’ agencies, self-managed super fund (SMSF) property valuation, stamp duty assessments, tax depreciation schedules and tenant representation. The firm serves property classes such as residential, commercial, rural, agribusiness and government portfolios.
🙌 Performance (5Yr p.a)
-8.00%
📊 Share price
$0.09 AUD
🏠 REAL ESTATE
Audalia Resources Ltd. engages in the exploration of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-07-06. The firm's Medcalf Project is a vanadium-titanium-iron project located approximately 470 kilometers (kms) southeast of Perth near Lake Johnston, Western Australia. The Medcalf Project lies in the southern end of the Archaean Lake Johnston greenstone belt. The greenstone belt is a narrow, north-northwest trending belt approximately 110 kms in length. The Medcalf Project comprises of one granted exploration license E63/1855, two miscellaneous licenses L63/75 and L63/94, and two General Purpose licenses G63/10 and G63/12 as well as mining lease M63/656. Together these licenses cover a total area of 38 square kilometers. The firm has developed two products in the market from the Medcalf Project. The products include high titanium lump ore and concentrate fine ore. The firm also applied for three exploration licenses within a 30km radius of the Medcalf Project.
🙌 Performance (5Yr p.a)
26.67%
📊 Share price
$0.02 AUD
📈 HIGH PRICE GROWTH
⛏️ MINING
Acorn Capital Investment Fund Ltd is a AU-based company operating in industry. The company is headquartered in Melbourne, Victoria and currently employs 0 full-time employees. The company went IPO on 2014-05-01. Acorn Capital Investment Fund Limited is an Australia-based investment company. The principal activity of the Company is to invest in a portfolio of listed and unlisted microcap companies. The objective of the Company is to create a diversified portfolio of listed microcap companies and then to invest opportunistically in unlisted entities that offer better relative value. The firm invests in various sectors, including consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, materials, communication services, utilities, financials and cash. The Company’s investment manager is Acorn Capital Limited.
🙌 Performance (5Yr p.a)
-6.01%
📊 Share price
$0.82 AUD
💰 HIGH DIVIDEND
🕊️
Social Score
35
An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.